← Back to patent-cliff list
R-906289 Monosodium
Tier C — Watch / tradeR-906289 Monosodium
Rigel Pharmaceuticals
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IRAK1, IRAK4
Indications (approved)：Myelodysplastic syndrome
Regional status
US
Phase II
2022-09-12
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of R-906289 Monosodium?
Approved indications include: Myelodysplastic syndrome.
When does the R-906289 Monosodium patent expire?
No public expiry year is available for R-906289 Monosodium yet; this page updates once verified.
How do I get a quote for R-906289 Monosodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05